Disulfiram and Acamprosate

Overview

Two Different Strategies for AUD

Disulfiram and acamprosate take fundamentally different approaches to alcohol use disorder. Disulfiram is a deterrent — it makes drinking physically unpleasant by creating a buildup of acetaldehyde, a toxic intermediate of alcohol metabolism. The threat of the reaction, more than the reaction itself, is meant to support abstinence. Acamprosate is a stabilizer — it dampens the lingering neurochemical disturbance that follows acute withdrawal, reducing the anxiety, sleep disturbance, and dysphoria that often drive relapse weeks into recovery.

Both medications have been available for decades. Disulfiram was approved by the FDA in 1951, making it one of the oldest medications in psychiatric practice. Acamprosate was approved by the FDA in 2004, having been used in Europe for many years prior. Each has its own evidence base, ideal patient profile, and limitations.

The Third Pillar of AUD Treatment

In contemporary addiction medicine, the FDA-approved medications for AUD are naltrexone (oral and extended-release injection), acamprosate, and disulfiram. Each addresses a different mechanism. Naltrexone reduces the rewarding effect of alcohol. Acamprosate reduces protracted withdrawal symptoms. Disulfiram creates an aversive consequence to drinking. The choice among them depends on patient goals, comorbidities, adherence considerations, and clinical context. They can sometimes be used in combination, though this is more specialty-driven.

Goals: Abstinence vs Reduction

Modern AUD treatment recognizes that goals can range from complete abstinence to reduced or moderate drinking. Disulfiram supports an abstinence goal — drinking on disulfiram is unpleasant and potentially dangerous. Acamprosate is also generally framed around abstinence and is most effective in patients who have completed detoxification. Naltrexone, by contrast, can support either abstinence or moderation goals. Matching the medication to the patient's goal increases the chance of meaningful benefit.

How They Work

Disulfiram: Disrupting Alcohol Metabolism

Alcohol is metabolized in the liver in two main steps. First, alcohol dehydrogenase converts ethanol to acetaldehyde — a toxic, irritating compound responsible for many of the unpleasant effects of drinking. Second, aldehyde dehydrogenase (ALDH) converts acetaldehyde into acetate, which is further metabolized into harmless byproducts. Disulfiram irreversibly inhibits aldehyde dehydrogenase, causing acetaldehyde to accumulate when alcohol is consumed.

The acetaldehyde buildup produces the "disulfiram reaction": flushing, throbbing headache, nausea, vomiting, sweating, palpitations, weakness, dizziness, dyspnea, and in severe cases hypotension and cardiac complications. Even small amounts of alcohol — including those in mouthwash, certain foods, or topical products — can trigger reactions. The presence of disulfiram in the body is the deterrent; the actual reaction need not occur frequently for the medication to work, since the threat itself shapes behavior.

Acamprosate: Glutamate and GABA Modulation

Chronic heavy alcohol use produces neuroadaptive changes that include upregulation of the excitatory glutamatergic NMDA receptor system and downregulation of inhibitory GABAergic signaling. When drinking stops, this imbalance becomes acute — manifesting first as the classic withdrawal syndrome (anxiety, tremor, autonomic activation, and in severe cases seizures and delirium tremens) and then as a more protracted disturbance of mood, sleep, and craving that can persist for weeks to months. This "post-acute withdrawal syndrome" or PAWS is a major driver of relapse.

Acamprosate is thought to modulate this glutamate/GABA imbalance, dampening the excitatory hyperactivity and reducing post-acute withdrawal symptoms. The exact molecular mechanism is incompletely understood, with proposed actions at NMDA, metabotropic glutamate, and GABA receptor systems. The result, clinically, is reduced relapse to heavy drinking in patients who have completed acute detoxification and are committed to abstinence.

Timing Matters

The differential mechanism explains why each medication has its niche. Disulfiram is started only after abstinence is achieved and is intended to maintain that abstinence by raising the cost of any single lapse. Acamprosate is also started after detoxification — typically within days of the last drink — and works by smoothing the bumpy course of early sobriety. Naltrexone, with its different mechanism, can be started at various points and does not require prior abstinence.

Major Medications in This Class

Disulfiram (Antabuse)

Disulfiram is a once-daily oral medication, typically dosed at 250 mg per day (range 125–500 mg). It is taken in the morning, when commitment to abstinence is often easiest. The medication's effect persists for up to two weeks after the last dose because of its irreversible binding to ALDH; the body must synthesize new enzyme.

Supervised dosing — by a family member, partner, pharmacy, or treatment program — substantially improves outcomes by ensuring adherence. Patients who take disulfiram irregularly can simply skip doses when planning to drink, undermining the medication's effect. The decision to use disulfiram should always be made with the patient's full understanding and consent, since the deterrent depends on knowing the medication is active.

Acamprosate (Campral)

Acamprosate is dosed three times daily, typically 666 mg per dose (two 333 mg tablets), for a total of about 2 grams per day. The thrice-daily dosing is a major barrier to adherence for many patients. Acamprosate is renally excreted, so dosing must be reduced in renal impairment and the medication is generally avoided in severe renal disease.

Acamprosate is most effective when started shortly after detoxification and continued for at least several months. It is best suited to patients who are committed to abstinence and who can manage the three-times-daily regimen.

How They Compare with Naltrexone

Naltrexone differs from both disulfiram and acamprosate in mechanism (opioid receptor blockade), in dosing (once daily oral or monthly injection), and in the goal it best supports (works for both abstinence and reduction). For a patient who cannot fully commit to abstinence, naltrexone is often a better fit. For a patient who is fully abstinent and wants additional support against relapse, acamprosate may be added or used as alternative. For a patient who wants a strong external deterrent and has a supportive structure for supervised dosing, disulfiram may be considered.

FDA-Approved and Off-Label Uses

Disulfiram for Alcohol Use Disorder

Disulfiram is FDA-approved as an aid in the management of selected patients with chronic alcoholism who want to remain abstinent. It is not a cure and does not address craving directly; rather, it provides an external structure that supports abstinence by raising the consequences of drinking. Evidence is strongest in studies that combine disulfiram with supervised dosing and psychosocial support.

Acamprosate for Alcohol Use Disorder

Acamprosate is FDA-approved for the maintenance of abstinence from alcohol in patients with AUD who are abstinent at treatment initiation. It is used as part of a comprehensive treatment plan that includes psychosocial support. Trials suggest modest but meaningful benefit in maintaining abstinence and reducing the risk of return to heavy drinking.

Selecting Among Options

There is no single "best" medication for AUD. Clinical guidelines from the American Psychiatric Association, the Department of Veterans Affairs and the Department of Defense, and SAMHSA support naltrexone or acamprosate as first-line options for many patients, with disulfiram as a strong option for selected patients. The decision should be made collaboratively with the patient, taking into account goals, comorbidities, adherence factors, and personal preference.

Off-Label Considerations

Disulfiram has been investigated for cocaine use disorder, with mixed results. Acamprosate has been investigated for other compulsive behaviors and for some neurological conditions, with limited evidence. Neither has established off-label indications comparable in evidence to their AUD use.

Combination Approaches

Naltrexone and acamprosate are sometimes used together in patients who want maximal pharmacological support; the combination is well-tolerated and may offer modest additional benefit. Combining disulfiram with naltrexone is less commonly recommended, though specialty practice occasionally does so. Combination decisions are individualized.

Common and Serious Side Effects

Disulfiram

• Drowsiness and fatigue (often improves)
• Metallic or garlic-like aftertaste
• Headache
• Decreased libido and erectile dysfunction
• Acneiform skin reactions
• Peripheral neuropathy (uncommon, but can be severe; usually with prolonged use)
• Optic neuritis (rare)
• Hepatotoxicity (uncommon, but potentially severe and unpredictable)
• Psychiatric effects (rare, including psychosis or mood change)

The Disulfiram-Alcohol Reaction

If alcohol is consumed while disulfiram is active, the resulting reaction includes flushing, headache, nausea, vomiting, palpitations, dyspnea, sweating, weakness, blurred vision, confusion, and in severe cases hypotension, cardiac complications, seizures, or death. The reaction can be triggered by very small amounts of alcohol, including those in cough syrups, mouthwash, certain foods, vinegars, and even some skin and inhaled products. Because of the cardiovascular risks, disulfiram is contraindicated in significant cardiovascular disease.

Acamprosate

• Diarrhea (the most common side effect)
• Nausea
• Flatulence and abdominal discomfort
• Insomnia, anxiety, sleep disturbance
• Itching
• Headache
• Rarely: suicidal ideation (the FDA notes this in labeling, with attention to monitoring)

Renal Considerations

Acamprosate is renally cleared. Dosing must be reduced in moderate renal impairment, and the medication should generally be avoided in severe renal impairment. Baseline and periodic renal function testing is appropriate.

Hepatic Considerations

Disulfiram has been associated with rare but serious hepatotoxicity. Baseline liver function tests and periodic monitoring are part of standard practice. Acamprosate is not significantly hepatically metabolized and is often preferred when liver disease is present.

Drug Interactions and Warnings

Disulfiram and Alcohol-Containing Products

The disulfiram reaction can be triggered by alcohol from many sources beyond beverages: cooking wines, sauces, certain desserts, mouthwashes, hand sanitizers (when ingested or, less commonly, with heavy topical exposure), some cough and cold syrups, certain elixir formulations of medications, and some skin lotions and aftershaves. Patients should be educated about these sources and carry a medication card identifying them as disulfiram users.

Disulfiram and Metronidazole

Combining disulfiram with metronidazole (an antibiotic) can cause psychosis, confusion, and severe reactions. This combination is contraindicated.

Disulfiram and Other Medications

Disulfiram inhibits several cytochrome P450 enzymes and can raise levels of warfarin, phenytoin, theophylline, certain benzodiazepines, and many other medications. New prescriptions should be carefully reviewed for interactions.

Acamprosate Interactions

Acamprosate has relatively few drug interactions because it is renally cleared and not significantly metabolized. This profile makes it useful in polypharmacy contexts. The major considerations are renal function and gastrointestinal tolerability.

Combination with Other AUD Medications

Naltrexone and acamprosate are sometimes combined; the combination is generally well-tolerated. Combinations involving disulfiram are less common and require careful consideration.

Pregnancy

Disulfiram is generally avoided in pregnancy due to limited safety data and theoretical concerns. Acamprosate is also generally avoided in pregnancy when alternatives are available. Both decisions are individualized and require specialty input, balancing the risks of untreated AUD with medication considerations.

Starting, Monitoring, and Stopping

Pre-Treatment Evaluation

Before starting disulfiram, prescribers typically assess cardiovascular health, hepatic function, baseline medications and supplements, the patient's understanding of the medication and its reactions, the support system available to ensure adherence, and the absence of alcohol in the system. For acamprosate, renal function is the central consideration, along with depression and suicidality screening.

Initiating Disulfiram

Disulfiram is typically started after at least 12–24 hours of complete alcohol abstinence. Doses begin at 250 mg per day and may be adjusted. Supervised dosing — by a partner, family member, or program — improves adherence. Patients should be given an unambiguous explanation of what the medication does, what reactions look like, and what alcohol sources to avoid.

Initiating Acamprosate

Acamprosate is started after detoxification — typically within days of the last drink. The full dose (typically 666 mg three times daily) is generally started directly rather than titrated. Patients are educated about the three-times-daily regimen and helped to develop strategies for adherence.

Monitoring

• Liver function tests at baseline and periodically with disulfiram
• Renal function at baseline and periodically with acamprosate
• Alcohol use, craving, mood, and overall function
• Side effects and emergence of new symptoms
• Concurrent medications added since the last visit

Duration of Treatment

There is no fixed duration for either medication. Acamprosate is typically continued for at least 6–12 months in successful treatment, often longer. Disulfiram can be used as long as the patient and prescriber agree that the structure remains helpful. Tapering is generally not necessary for either medication, though stopping disulfiram requires awareness that alcohol effects return only after the body has regenerated ALDH (about two weeks).

Special Populations

Older Adults

Older adults are increasingly affected by AUD but are particularly vulnerable to the cardiovascular consequences of the disulfiram-alcohol reaction. Disulfiram is used cautiously, if at all, in this population. Acamprosate is generally well-tolerated in older adults, with attention to renal function.

Pregnancy and Lactation

Both medications are generally avoided in pregnancy when alternatives are available. Untreated AUD in pregnancy carries its own significant risks for the developing fetus, and decisions involve specialty input. Lactation data are limited for both.

Renal and Hepatic Impairment

Acamprosate requires dose reduction in moderate renal impairment and is avoided in severe impairment. Disulfiram should be used cautiously in significant hepatic disease and is generally avoided in advanced cirrhosis or active hepatitis.

Cardiovascular Disease

Significant cardiovascular disease (recent myocardial infarction, severe heart failure, significant coronary disease) is a contraindication or strong caution for disulfiram because of the cardiovascular components of the disulfiram-alcohol reaction.

Co-occurring Mental Health Conditions

Many patients with AUD have co-occurring depression, anxiety, PTSD, or bipolar disorder. Integrated treatment is the standard. Acamprosate has rare reports of suicidal ideation, so depression and suicidality should be monitored. Disulfiram has rare reports of psychiatric reactions, also warranting attention.

Court-Mandated Treatment

Disulfiram has historically been used in court-ordered or contingency-based treatment settings, where supervised dosing improves adherence. Ethical practice requires the patient's understanding and consent, even in mandated contexts.

Controversies and Modern Practice

Why Is AUD Pharmacotherapy Underused?

Despite three FDA-approved medications with established evidence, only a small minority of people with AUD ever receive medication. The reasons include lack of clinician familiarity, persistent belief that AUD is a willpower problem rather than a medical condition, fragmented care systems that separate addiction treatment from general medicine, insurance and access barriers, and patient unfamiliarity with the option. Expanding AUD pharmacotherapy access is a major focus in modern addiction medicine.

Disulfiram in the Era of Naltrexone

Some addiction physicians consider disulfiram obsolete given the availability of naltrexone, which is generally easier to use and lacks the cardiovascular risk of the disulfiram reaction. Others maintain that disulfiram retains a place for selected patients — particularly those who do not respond to naltrexone, who have a stable support system for supervised dosing, and who specifically want a deterrent. The role of disulfiram is debated more than its existence.

Effectiveness of Acamprosate

European trials of acamprosate were generally more positive than the US registration trial, which was less favorable. Meta-analyses suggest modest benefit, particularly for abstinence maintenance after detoxification. The differential findings have been attributed to differences in treatment settings, patient populations, and goal definitions across studies. Acamprosate remains a guideline-supported option.

Goal Definitions

Modern AUD treatment increasingly acknowledges that abstinence is not the only valid goal. For patients seeking reduced drinking, naltrexone is generally a better fit than acamprosate or disulfiram. For patients seeking abstinence, all three medications can be considered. Aligning the medication with the patient's stated goal increases the likelihood of engagement and benefit.

Combining Medication with Psychosocial Treatment

Medication is most effective when combined with psychosocial support — cognitive behavioral therapy, motivational interviewing, mutual-help groups, family involvement, and attention to social determinants. The combination consistently outperforms either approach alone.

What Patients Should Know

Disulfiram: What to Expect

Taking disulfiram is a commitment to abstinence. Patients should know that the medication will produce an unpleasant reaction with any meaningful alcohol exposure, that the effect lasts for up to two weeks after stopping, that many products contain alcohol unexpectedly, and that the reaction can include severe cardiovascular effects in some people. A wallet card identifying disulfiram use can be valuable for emergency settings.

Hidden Sources of Alcohol

Patients on disulfiram should be aware of alcohol in:

• Mouthwashes containing alcohol
• Cooking with wine, beer, or spirits (even when "cooked off")
• Vinegars and salad dressings in some quantities
• Cough and cold syrups
• Some elixir-form medications
• Hand sanitizers if ingested or, less commonly, with heavy topical exposure
• Certain aftershaves and skin products
• Sauces and desserts in restaurants

Acamprosate: What to Expect

Acamprosate is taken three times daily with or without food. It does not produce immediate noticeable effects in most patients. Its benefit accrues over weeks as it stabilizes the post-acute withdrawal experience. Diarrhea is the most common side effect and usually improves over time. Setting reminders, using a pill organizer, or pairing doses with meals can help with adherence.

Communicating with Other Clinicians

Patients on disulfiram or acamprosate should inform all clinicians, including dentists and surgeons, before procedures or new prescriptions. Pharmacist consultation when starting new medications can identify interactions, particularly for disulfiram.

Combining with Psychosocial Treatment

Medications work best as part of a broader treatment plan. Therapy, mutual-help groups (AA, SMART Recovery, Refuge Recovery, others), family involvement, and attention to mental health and life circumstances all contribute to outcomes. Medication alone is rarely the complete answer.

If You Relapse

Relapse is a common part of recovery from AUD, not a sign of failure. Patients should know how to contact their treatment team if a lapse occurs and should not assume that a lapse means medication is not working. Adjusting the treatment plan, considering different medications, intensifying psychosocial support, or addressing co-occurring conditions are often more useful than stopping treatment altogether.